Regular versus As-needed Treatments for Mild Asthma in Children, Adolescents, and Adults: A Systematic Review and Network Meta-analysis

Abstract

Background Inhaled corticosteroids (ICS) are recommended treatment for mild asthma. We aimed to update the evidence on the efficacy and safety of ICS-containing regimens, leukotriene receptor antagonists (LTRA), and tiotropium relative to as-needed (AN) short-acting β2-agonists (SABA) in children (aged 6 − 11 years) and adolescents/adults. Methods A systematic review of randomized controlled trials (RCTs) of regular and AN treatment for mild asthma was conducted. PubMed, Scopus, and ClinicalTrials.gov were searched up to 31st March 2024. RCTs in children or adolescents/adults with mild asthma were eligible if they compared any of the following treatments: ICS alone or in combination with fast-acting bronchodilators (FABA, i.e., formoterol or SABA) or long-acting β2-agonists (LABA), LTRA, tiotropium, and SABA alone, for the following outcomes: exacerbations, asthma symptoms, forced expiratory volume in 1 s (FEV₁), asthma-specific quality-of-life (QoL), or severe adverse events (SAEs). Network meta-analysis (NMA) was used to pool risk ratios (RR) or mean differences for treatment outcomes. Results Thirteen RCTs in children, and 29 in adolescents/adults were included. Regular ICS ranked best for preventing exacerbations and improving FEV₁ in children. NMA of RCTs suggested regular ICS were better in preventing exacerbations than LTRA (RR [95% confidence intervals], (0.81[0.69,0.96]) and AN-SABA (0.61[0.48,0.78]), similar to AN-ICS (0.83[0.62,1.12]). In adolescents/adults, for preventing severe exacerbations, regular ICS outperformed AN-SABA (0.58[0.46,0.73]), but AN-ICS/FABA (0.73[0.54,0.97]), and regular ICS/LABA (0.68[0.48,0.97]) surpassed regular ICS. Symptom relief and improved FEV₁ were similar among the ICS-containing regimens. Regular ICS ranked best for improved QoL and least likely for SAEs. Conclusions Regular ICS use ranked best for exacerbation prevention and increasing FEV₁ in children with mild asthma. In adolescents/adults, ICS-containing regimens outperformed AN-SABA for exacerbation prevention. Severe exacerbation risk was lowered in regular ICS use than AN use in patients with low FEV₁. Furthermore, regular ICS use enhances FEV₁ and QoL more than AN-SABA and LTRA.